UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~Form~~FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

~~PURSUANT~~For TOthe ~~RULE 13a-16 OR~~month ~~15d-16~~of March 2026

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-38245

Akso Health Group

(~~Translation~~Exact name of registrant~~’s name~~ ~~into~~as ~~English~~specified in its charter)

Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building,

No. 44, Moscow Road, Qianwan Bonded Port Area,

Qingdao Pilot Free Trade Zone, China (Shandong)

People’s Republic of China Tel: +86 152 1005 4919

(Address of ~~principal executive~~Principal ~~office~~Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~Interim~~Resignation ~~Financial~~and ~~Statements~~Appointment of Independent Directors

~~Akso~~Mr. Gerald T. Neal, an independent director of Akso Health Group is(the ~~furnishing~~“Company”), ~~this~~member ~~Form 6-K~~of tothe ~~provide~~audit ~~six-month~~committee ~~interim~~of ~~financial~~the ~~statements~~board of directors of the Company (the “Board”), chair of the compensation committee and ~~incorporate~~member ~~such~~of ~~financial~~the ~~statements~~nominating & corporate governance committee ~~into~~of the Board, notified the Company of his resignation as a director for personal reasons, effective February 28, 2026. Mr. Neal’s resignation ~~registration~~from ~~statements~~the ~~referenced~~Board ~~below~~was not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company.

~~This~~Effective ~~Form 6-K~~on isMarch ~~hereby~~16, ~~incorporated by reference into~~ 2026, the ~~registration statements~~board of ~~the~~directors ~~Company~~of (the “Company”) ~~on Form S-8 (Registration No~~appointed Mr. ~~333-223951)~~ ~~and~~Jianqiang ~~on Form F-3~~Xu, as ~~amended~~a ~~(Registration~~new ~~No.~~independent ~~No. 277351),~~director toof the ~~extent~~Board, ~~not~~as ~~superseded~~member byof ~~documents~~the oraudit ~~reports~~committee of ~~subsequently~~the ~~filed~~Board, orchair ~~furnished~~of by the ~~Company~~compensation ~~under~~committee ~~the~~and ~~Securities~~member ~~Act~~ of ~~1933,~~the asnominating ~~amended,~~& orcorporate governance committee of the ~~Securities~~Board. ~~Exchange~~The biographical ~~Act~~information of ~~1934,~~Mr. asNeal ~~amended~~is set forth below.

~~Financial~~Mr. ~~Statements~~Jianqiang Xu, aged 62, has extensive experience in neurosurgery and ~~Exhibits~~hospital administration. Mr. Xu currently serves as Director of the Department of Neurosurgery, Vice President, and President of Fengfeng Group General Hospital, a Class III Grade A hospital in China since 2016. He specializes in the microsurgical treatment of intracranial and intraspinal tumors. Mr. Xu has published more than 40 academic papers in core journals and SCI-indexed publications and has edited four professional books. He has also spoken at certain provincial, national, and international neurosurgery and trauma conferences in September 2017. Mr. Xu received a bachelor’s degree in Medicine in 1986 and a master’s degree in Surgery in June 2001.

~~Exhibits~~Mr. Xu does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

Exhibit No.		Description
99.1		Unaudited Interim Consolidated Financial Statements as of September 30, 2025 and for the Six Months Ended September 30, 2025 and 2024
99.2		Operating and Financial Review and Prospects in Connection with the Unaudited Interim Consolidated Financial Statements for the Six Months Ended September 30, 2025 and 2024
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Mr. Xu also entered into a director offer letter (the “Offer Letter”) with the Company which establishes other terms and conditions governing his service to the Company. The Offer Letter is qualified in its entirety by reference to the complete text of the Offer Letter, which is filed hereto as Exhibit 99.1.

Exhibits

Exhibit No.		Description
99.1		Director Offer Letter, dated March 20, 2026, by and between Jianqiang Xu and Akso Health Group

~~SIGNATURE~~SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, ~~hereunto~~ thereunto duly authorized.

Dated: February 10, 2026	Akso Health Group
	Akso Health Group
	By:	/s/ Yilin (Linda) Wang
	Name:	~~Name:~~Yilin (Linda) Wang	~~Yilin (Linda) Wang~~
	Title:	~~Title:~~Chief Executive Officer	~~Chief Executive Officer~~
Date: March 23, 2026

Filing Compare · Akso Health Group